Special Profile & Four Companies Where Investors are Anticipating Success

NEW YORK, NY -- June 3, 2015 – About Small Cap Traders and Four Brief Reports
Small Cap Traders makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of a profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

*Special Profile* - Two Clinical Stage Products Lead the Way in a Promising Pipeline and Large

Actinium Pharmaceuticals, Inc. (NYSE-MKT: ATNM), (“the company”) is a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The company develops cancer drugs, primarily using its Alpha Particle Immunotherapy Technology (“APIT) platform. This patented technology combines monoclonal antibodies (mAB) for targeting specific types of cells with alpha emitting radioisotopes (actinium-225 and bismuth-213), and specific beta emitting radiopharmaceuticals, to precisely target and kill cancerous cells. The Company’s products are based on patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC).

Company Highlights

- Completed secondary offering, resulting in approximately $18.4 million in proceeds.
- Attained Orphan-Drug Status for Actimab™-A.
- Announced filing for Investigational New Drug meeting with U.S. FDA to finalize development of Iomab™-B.
- Prepared for Phase 3 Trial of Iomab™-B and Phase 2 Trial of Actimab™-A by mid-year 2015.
- Merck a leading drug manufacturer holds a large position in company. (Makin ATNM a Possible Acquisition Target)

For a full analyst report on ATNM that includes a company overview, market and competition breakdown, recent events, outlook, valuation, analyst summary and recommendation can be viewed by using the following link at no cost: http://bit.ly/--ATNM--AnalystReport

Text "SmallCap" to 25827 to receive alerts quicker

4 Brief Reports:

Cellceutix Corp. (OTCBB: CTIX) is a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications.

CTIX has updated the progress of two of its leading product candidates, Kevetrin and Brilacidin-OM. In the report that follows you can get the details of the progress of these products: http://bit.ly/_CTIX_AnalystBrief

WMIH Corp. (OTCQB: WMIH) operates a single business through their wholly owned subsidiary, WM Mortgage Reinsurance Company, Inc., a Hawaii corporation, whose sole activity is the reinsurance of mortgage insurance policies that is operated in runoff mode.

Investors are anticipating a merger or acquisition for WMIH. Find out why and get further details in the following report: http://bit.ly/_WMIH_AnalystReport

Sphere 3D Corp. (NASDAQ: ANY) is a virtualization technology solution provider whose patent pending Glassware 2.0 ultra-thin client allows fully featured applications to be run on any cloud-connected device, independent of operating system or hardware, without sacrificing performance or security.

The company recently announced its new SnapCLOUD platform. Get all the information when you read the report at the link: http://bit.ly/_ANY_AnalystBrief

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer.

The company presented information about its Phase III bavituximab agent at a conference. Read about it in the report you will find here: http://bit.ly/_PPHM_AnalystBrief

Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by the profiled company or any related party. A full disclaimer can be found by viewing the full analyst report. We do not engage in high frequency trading or hold any positions of profiled company. We have not been compensated in any form for these reports.
For more information and services provided beyond this release please use contact information provided below. If you notice any errors or omissions, please notify us below.

A full disclaimer can be found by viewing the analyst report.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcaptraders.com. For any urgent concerns or inquiries please contact us at editor@smallcaptraders.com.

Source: Small Cap Traders
Contact: editor@smallcaptraders.com